Agilent price target raised to $140 from $134 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on Agilent (A) to $140 from $134 and keeps a Neutral rating on the shares after Alnylam (ALNY) reported positive topline data for the phase 3 HELIOS-B trial evaluating vutrisiran in ATTR-CM that the analyst calls a “best-case scenario.” Alnylam is a known key customer of Agilent’s NASD business and Agilent would benefit from a successful launch of vutrisiran in ATTR-CM, notes the analyst, who thinks the near-term benefit could be up to a roughly $150M tailwind to sales in 2025.